ATE501712T1 - Transdermale analgetische systeme mit reduziertem missbrauchspotential - Google Patents

Transdermale analgetische systeme mit reduziertem missbrauchspotential

Info

Publication number
ATE501712T1
ATE501712T1 AT03718492T AT03718492T ATE501712T1 AT E501712 T1 ATE501712 T1 AT E501712T1 AT 03718492 T AT03718492 T AT 03718492T AT 03718492 T AT03718492 T AT 03718492T AT E501712 T1 ATE501712 T1 AT E501712T1
Authority
AT
Austria
Prior art keywords
abuse potential
transdermal analgesic
analgesic systems
reduced abuse
reduced
Prior art date
Application number
AT03718492T
Other languages
English (en)
Inventor
Robert Gale
Thomas M Stein
Jay Audett
Jane Stepic
Joseph B Phipps
Michel J N Cormier
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Application granted granted Critical
Publication of ATE501712T1 publication Critical patent/ATE501712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03718492T 2002-04-23 2003-04-22 Transdermale analgetische systeme mit reduziertem missbrauchspotential ATE501712T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37511002P 2002-04-23 2002-04-23
PCT/US2003/012418 WO2003090729A1 (en) 2002-04-23 2003-04-22 Transdermal analgesic systems with reduced abuse potential

Publications (1)

Publication Number Publication Date
ATE501712T1 true ATE501712T1 (de) 2011-04-15

Family

ID=29270594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718492T ATE501712T1 (de) 2002-04-23 2003-04-22 Transdermale analgetische systeme mit reduziertem missbrauchspotential

Country Status (20)

Country Link
US (2) US8440220B2 (de)
EP (1) EP1513507B1 (de)
JP (2) JP2005526839A (de)
KR (1) KR20050050615A (de)
CN (2) CN101406703A (de)
AR (1) AR039336A1 (de)
AT (1) ATE501712T1 (de)
AU (2) AU2003221752A1 (de)
CA (1) CA2496454A1 (de)
DE (1) DE60336394D1 (de)
ES (1) ES2361068T3 (de)
IL (1) IL164760A0 (de)
MX (1) MXPA04010612A (de)
NO (1) NO20045034L (de)
NZ (1) NZ535971A (de)
PE (1) PE20031016A1 (de)
TW (1) TW200404581A (de)
UY (1) UY27773A1 (de)
WO (1) WO2003090729A1 (de)
ZA (1) ZA200409396B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
DE02715112T1 (de) * 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
AR047936A1 (es) * 2003-04-30 2006-03-15 Purdue Pharma Ltd Forma de dosificacion transdermica resistente a la manipulacion
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
EP1677771A2 (de) * 2003-10-30 2006-07-12 Alza Corporation Transdermale analgetische systeme mit reduziertem missbrauchspotential
US8535711B2 (en) * 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
LT2351555T (lt) * 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
US20050202073A1 (en) * 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) * 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
ATE471146T1 (de) 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
JP4936901B2 (ja) 2005-01-07 2012-05-23 ユニバーサル・バイオ・リサーチ株式会社 担体封入チップ、担体処理装置、および担体処理方法
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
WO2006124749A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against antagonist exposure
WO2006124584A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
CN101009530B (zh) * 2006-01-23 2012-02-15 华为技术有限公司 支持组播类业务的无源光网络、复用/解复用器及方法
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8989858B2 (en) 2007-12-05 2015-03-24 The Invention Science Fund I, Llc Implant system for chemical modulation of neural activity
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8170660B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for thermal modulation of neural activity
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009106831A2 (en) * 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
EP2254561A2 (de) * 2008-03-26 2010-12-01 AllTranz Inc. Missbrauchssichere transdermale formulierungen von opiat-agonisten und -agonist-antagonisten
US20100221313A1 (en) * 2008-12-01 2010-09-02 Innovative Pharmaceuticals, Llc Transdermal reservoir patch
CN101434708B (zh) * 2008-12-19 2012-01-11 成都中科来方能源科技有限公司 水性聚合物改性微孔聚烯烃隔膜及其制备方法和用途
PL2403482T3 (pl) 2009-03-04 2018-06-29 Emplicure Ab Preparat odporny na nadużywanie
PL2427177T3 (pl) 2009-05-08 2018-09-28 Emplicure Ab Kompozycja do przedłużonego podawania leku zawierająca geopolimerowy środek wiążący
DE102009036485B4 (de) * 2009-08-07 2012-10-04 Lts Lohmann Therapie-Systeme Ag Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
CA2795158C (en) * 2010-04-02 2019-10-22 Alltranz Inc. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
KR20150036825A (ko) 2010-04-13 2015-04-07 나지브 바불 1-메틸-2''-6''-피페콜옥실리디드의 피부 약제학적 조성물 및 사용 방법
WO2012032337A2 (en) 2010-09-07 2012-03-15 Orexo Ab A transdermal drug administration device
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
MX357423B (es) 2011-09-30 2018-07-09 Verde Environmental Tech Inc Sistema de desecho de medicamento general.
KR20140068058A (ko) 2011-09-30 2014-06-05 테이코쿠 팔마 유에스에이, 인코포레이티드 경피 패치 처리 시스템
PL3096746T3 (pl) * 2014-01-22 2019-09-30 4P Therapeutics Systemy transdermalne zapobiegające nadużywaniu i niewłaściwemu użyciu
US11607026B2 (en) 2014-05-30 2023-03-21 Johnson & Johnson Consumer Inc. Device for delivery of skin care composition
US10071090B2 (en) 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
WO2016049266A1 (en) 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (de) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Eingabe- und unterstützungssystem für heftiges verlangen
WO2017053936A1 (en) 2015-09-24 2017-03-30 Pain Therapeutic, Inc. Cocrystals of naloxone and naltrexone
GB201600919D0 (en) * 2016-01-18 2016-03-02 Buzzz Pharmaceuticals Ltd Transdermal patch
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
IL269957B (en) 2017-04-18 2022-08-01 Breakthrough Tech Llc Sulfur production
US12296129B2 (en) 2018-03-07 2025-05-13 Soovu Labs, Inc. Systems and methods for improved pain relief from stimulation of thermal fibers
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
DE102018216244A1 (de) * 2018-09-24 2020-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Barriereschicht
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
JP6912122B2 (ja) * 2019-02-28 2021-07-28 日本臓器製薬株式会社 経皮投与製剤
CN112810171B (zh) * 2021-01-22 2025-10-31 东莞市高贝瑞自动化科技有限公司 一种耳机套全自动生产线
WO2022249748A1 (ja) * 2021-05-24 2022-12-01 住友精化株式会社 ゲル状組成物
US20240245892A1 (en) * 2021-10-22 2024-07-25 Georgetown University Non-Invasive and Passive Transdermal Drug Delivery Patch For Parkinson's Disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US5310559A (en) 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US5186939A (en) 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US5783583A (en) 1996-04-12 1998-07-21 Simon; David Lew 17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol, hydrochloride salt for the purpose of rapid narcotic detoxification
US6103258A (en) * 1996-04-12 2000-08-15 Simon; David Lew Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics
TW411277B (en) 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU4990797A (en) 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
DE19653605C2 (de) 1996-12-20 2002-11-28 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme und dessen Verwendung zur Herstellung eines transdermalen Therapiesystems
DE19653606A1 (de) 1996-12-20 1998-06-25 Roehm Gmbh Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
DE02715112T1 (de) * 2001-03-16 2007-04-19 Alza Corp., Mountain View Transdermales pflaster zur verabreichung von fentanyl
EP2062573B1 (de) * 2001-05-01 2011-11-16 Euro-Celtique S.A. Missbrauchssichere Opioide mit transdermalen Systemen
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
EP1530469B1 (de) * 2002-08-20 2009-02-25 Euro-Celtique S.A. Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
EP1677771A2 (de) * 2003-10-30 2006-07-12 Alza Corporation Transdermale analgetische systeme mit reduziertem missbrauchspotential

Also Published As

Publication number Publication date
PE20031016A1 (es) 2003-11-29
UY27773A1 (es) 2003-09-30
NO20045034L (no) 2005-01-19
ZA200409396B (en) 2006-07-26
KR20050050615A (ko) 2005-05-31
EP1513507A1 (de) 2005-03-16
NZ535971A (en) 2007-07-27
CN101406703A (zh) 2009-04-15
AU2009202407A1 (en) 2009-07-09
JP5453211B2 (ja) 2014-03-26
DE60336394D1 (de) 2011-04-28
AR039336A1 (es) 2005-02-16
US20130251760A1 (en) 2013-09-26
US8747889B2 (en) 2014-06-10
JP2011057684A (ja) 2011-03-24
WO2003090729A1 (en) 2003-11-06
CN1720028A (zh) 2006-01-11
US8440220B2 (en) 2013-05-14
CA2496454A1 (en) 2003-11-06
ES2361068T3 (es) 2011-06-13
MXPA04010612A (es) 2005-07-14
TW200404581A (en) 2004-04-01
IL164760A0 (en) 2005-12-18
JP2005526839A (ja) 2005-09-08
AU2003221752A1 (en) 2003-11-10
US20040013716A1 (en) 2004-01-22
EP1513507B1 (de) 2011-03-16

Similar Documents

Publication Publication Date Title
DE60336394D1 (de) Transdermale analgetische systeme mit reduziertem missbrauchspotential
IL175313A0 (en) Transdermal analgesic systems having reduced abuse potential
DE60308332D1 (de) Chinazolinverbindungen mit therapeutischem nutzen
DE60327864D1 (de) Ballondissektor mit kanüle
DE60334706D1 (de) Ür
DE60318974D1 (de) Elektronisches Schlüsselsystem
IS7689A (is) Fjölþátta lyfjaskammtaform
DE60222471D1 (de) Radareinrichtung
DE60325530D1 (de) Repositionsvorrichtung
DE50303054D1 (de) Phenyl-substituierte pyrazolopyrimidine
BR0307590B1 (pt) Laminado
EP1494530A4 (de) Kombinationstherapie mit kleepeptiden
DE60326373D1 (de) Gaspedal
DE50305924D1 (de) Schichtsystem
EP1550548A4 (de) Laminierungssystem
DE60314221D1 (de) Raupenfahrzeug
NO20044269L (no) Smamolekylaere inntrengningsinhibitorer
DE60322785D1 (de) Datenprozessor mit verzögerter Verzweigung
DE602004030300D1 (de) Datenschaltung mit Softwarekonfiguration
DK1594859T3 (da) Indazolamider med analgetisk aktivitet
NO20021944L (no) Slepebåt
NO20041579D0 (no) Klostillende midler
DE60237550D1 (de) Nockenvorrichtung
ITMI20022658A1 (it) Farmaci per il dolore cronico.
DE50311350D1 (de) Zens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties